Clipping of news on Brazilian Culture, Law and Citizenship
17/08/2011
This article was translated by an automatic translation system, and was therefore not reviewed by people.
Treatment with the neurotoxin are effective for diseases characterized by excessive muscle contractions such as dystonias and spasticity.
The neurotoxin coming from the bacterium Clostridium botulinum, commonly found in water, contaminated food (and canned foods, for example) and in the air, and that thousands of people know as the 'miracle' to the end of lines, has been used in therapeutically since the 1980s, before it has proven its effectiveness for aesthetic treatments.
When testing the substances corrective strabismus, the ophthalmologist Alan B. U.S. Scott noted that botulinum toxin type A relaxing certain muscles to be injected. In 1970, the FDA (Food and Drug Administration) - U.S. government agency that controls the food and pharmaceutical industries in the U.S. - the use of the toxin released on a trial basis for a group of researchers led by Scott, and later in that decade, the drug was applied in humans to treat strabismus.
In the decade following the first study was published showing the results for the treatment of spasticity - muscle contraction due to excessive central nervous system lesions such as tumors, stroke (stroke), cerebral palsy, multiple sclerosis and traumatic brain injury.
In later years, they discovered the benefits of botulinum toxin type A for diseases characterized by excessive muscle contractions such as dystonia - involuntary muscle contractions, repetitive and slow muscles in the neck, face and arms, for example, blefaroespamo - involuntary contractions of the eyelids - and some types of tremors.
Today in Brazil, although the botulinum toxin is best known for its use in cosmetic procedures, represents an unprecedented improvement in quality of life of thousands of people with neurological disorders. The product of high added value, are filed in the SUS (Unified Health System) and, therefore, the patient may require you to free or request a refund, provided you have a prescription.
The physiatrist Dr. Tae Chung Mo, a professor at the Faculty of Medicine, University of São Paulo and industry benchmark, said that before the discovery of the therapeutic potential of the toxin, neurological disorders were treated with oral medications, which besides having also had short side effect too aggressive. "Today, our first choice for the treatment of neurological disorders is always the botulinum toxin," says Dr. Tae.
He also said that the toxin suggests the patient with neurological disorder, their return to society. "Diseases such as dystonia, for example, move with the patient's self-esteem, even leading him to depression. Botulinum toxin has been meeting, also to your emotional health," adds Dr. Tae.
In Hospital, where Dr. Tae directs the Department of Neurophysiology and Neuromuscular Block Unit of the Institute of Rehabilitation Medicine, adherence to treatment is great. "It is very difficult to abandon a patient with dystonia treatment. It is functionally normal, so feels the need to correct muscle contraction that hampers the day-to-day." But the spastic patient, who lives with sequelae of diseases - such as stroke and cerebral palsy - adhere less to treatment, which brings the toxin improves but does not cure the deficiency.
For any of the diseases where botulinum toxin type A is indicated, treatment should be comprehensive and prescribed by a multidisciplinary team.
How the body works? In order for muscles to contract causing movement, is the release of the neurotransmitter acetylcholine by the nerves at the neuromuscular junction (synapse). Botulinum toxin type A acts by blocking the production of acetylcholine and, thus, temporarily relaxes the muscle that was injected. "The muscle injected with the toxin, is weakened, flaccid, for about six months, until the body absorbs the product," says Dr. Tae.
He points out that it is essential to the doctor who makes the application of the drug (usually neurologists or physiatrists) proper training. "Another need is an evaluation of the quality of the toxin," he adds.
Currently there are five laboratories in the world that produce botulinum toxin type A and the differences between them are small. Xeomin ®, Merz-Biolab, is the only market that does not contain protein complexes, so it is more refined and represents a lower risk of antibody formation, thus ensuring greater security to the patient who needs to use higher doses of the product and require repeated treatments.
The effect of botulinum toxin type A starts 48 to 72 hours after application and has maximum effect between one to four weeks, with an average of six weeks to six months. After the effect of the neurotoxin, the patient should receive another application.
Merz-Biolab-In 2009, the German group Merz Pharmaceuticals GmbH and the Brazilian pharmaceutical Biolab formed a joint venture to operate in the Brazilian market with a focus on therapy and aesthetics. The German drug has over 100 years and has always excelled in the research to formulate products for central nervous system. The presence of its products in Brazil occurred through licenses granted to the laboratory Biolab. In turn, Brazil is a leader in Biolab prescription of cardiovascular products and occupies the 9th position in the ranking of ethical drugs sold by prescription.
With investment of 20 million for setting up the structure in the state capital, was founded that year an independent company, Biolab-Merz Pharmaceuticals, which sells drugs and other Xeomin ®, the only botulinum toxin type A free and protein complexes that must be maintained at room temperature without refrigeration in transport and storage.
Xeomin ®, which was developed by Merz and released in Germany in 2005, competes directly with Botox ® (Allergan) and is currently marketed in 21 countries for cosmetic and therapeutic procedures.
The botulinum toxin market in Brazil is estimated at R$ 180 million a year, behind only the United States, with an average of U$ 450 million. Aesthetics accounts for 70% of this amount. (Source: IMS - MAT April 2011) In addition to botulinum toxin, the Merz-Biolab operates in the volumizing. Widely used in the global aesthetic market, the Radiesse ® is a volumizer fully resorbable and biocompatible, based on uniform particles of calcium hydroxyapatite and aqueous gel leading to the formation of new collagen, providing immediate and lasting result, resetting the form of natural way.
Radiesse ® is indicated for the increase in the volume of skin tissue and requires less amount of injected compared to other available fillers.
Source: Prontuário de Noticias
Our news are taken in full from our partner sites. For this reason, we can not change their content even in cases of errors.
This article was translated by an automatic translation system, and was therefore not reviewed by people.